No attachments available.
TECHNOLOGY LICENSING OPPORTUNITY: Clathrate Therapeutics Platform
Contact and place of performance
Caleb Ledgerwood
Los Alamos, NM 87545
USA
This technology from scientists at Los Alamos National Laboratory represents a novel platform for improving the safety and effectiveness of therapeutic gas-based treatments by enabling controlled, localized delivery at the site of disease. By addressing longstanding challenges associated with systemic exposure and dosing precision, the platform enhances the clinical viability of gas therapies across high-value market...
View moreHow it Works:
The Clathrate Therapeutics Platform uses a proprietary, controlled-release system designed to localize therapeutic gases at the intended treatment site rather than allowing them to disperse systemically. This technology temporarily stabilizes the gas within a biocompatible structure that gradually releases it under physiological conditions, enabling sustained and targeted exposure. This controlled release approach is designed to support therapeutic concentrations where needed while limiting circulating levels elsewhere in the body. An integrated computational modeling capability further supports optimization of dosing profiles and treatment parameters, helping guide development decisions prior to in vivo studies.
Key Advantages:
Market Applications:
Development Status: TRL 2
US patent pending
LA-UR-26-22810
LANL Tech Partnerships: Unlock the Innovative Potential
Los Alamos National Laboratory offers a wide range of cutting-edge technologies and capabilities that may provide your company with a competitive edge in the market and unlock the innovative potential that can enhance, refine, and revolutionize your products.
LANL’s licensing program focuses on moving inventions developed by our researchers to commercial innovations. Patented and patent pending inventions and copyrighted software are available to existing and start-up companies through exclusive and non-exclusive licensing agreements. For specific discussions, please contact [email protected].
Note: This is not a call for external services for the development of this technology.
https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology
m.lanl.gov/tech-search
This special notice, identified by solicitation number S-195396, details a technology licensing opportunity for the Clathrate Therapeutics Platform developed by scientists at Los Alamos National Laboratory. The technology offers a novel platform for improving the safety and effectiveness of therapeutic gas-based treatments through controlled, localized delivery at disease sites. By stabilizing gases within a biocompatible structure that releases under physiological conditions, the platform aims to address challenges related to systemic exposure and dosing precision in oncology, cardiovascular care, neurology, and regenerative medicine.
The Department of Energy, through its contractor Triad, is seeking partners to transition this invention into commercial innovations through exclusive or non-exclusive licensing agreements. The platform includes a proprietary controlled-release system and integrated computational modeling capabilities designed to optimize dosing profiles and reduce technical risk during development. This opportunity is classified under NAICS 325412 for Pharmaceutical Preparation Manufacturing and PSC 6505 for Drugs and Biologicals. There is no set-aside for this notice, and the associated technology is currently at Technology Readiness Level 2 with a U.S. patent pending.
Administrative and technical oversight is managed by the Los Alamos National Laboratory in Los Alamos, New Mexico, with Caleb Ledgerwood serving as the point of contact. The response deadline for this licensing opportunity is December 4, 2026. This notice is specifically for the licensing of existing intellectual property and does not constitute a request for external development services.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.